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Abstract
Objective—To examine the costs and cost-effectiveness of full implementation of biennial bowel
cancer screening for Australian residents aged 50–74 years.
Design and setting—Identification of existing economic models from 1993 to 2010 through
searches of PubMed and economic analysis databases, and by seeking expert advice; and
additional modelling to determine the costs and cost-effectiveness of full implementation of
biennial faecal occult blood test screening for the five million adults in Australia aged 50–74
years.
Main outcome measures—Estimated number of deaths from bowel cancer prevented, costs,
and cost-effectiveness (cost per life-year gained [LYG]) of biennial bowel cancer screening.
Results—We identified six relevant economic analyses, all of which found colorectal cancer
(CRC) screening to be very cost-effective, with costs per LYG under $55 000 per year in 2010
Australian dollars. Based on our additional modelling, we conservatively estimate that full
implementation of biennial screening for people aged 50–74 years would have gross costs of $150
million, reduce CRC mortality by 15%–25%, prevent 300–500 deaths from bowel cancer, and
save 3600–6000 life-years annually, for an undiscounted cost per LYG of $25 000–$41 667,
compared with no screening, and not taking cost savings as a result of treatment into
consideration. The additional expenditure required, after accounting for reductions in CRC
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incidence, savings in CRC treatment costs, and existing ad-hoc colonoscopy use, is likely to be
less than $50 million annually.
Conclusions—Full implementation of biennial faecal occult blood test screening in Australia
can reduce bowel cancer mortality, and is an efficient use of health resources that would require
modest additional government investment.
Colorectal cancer (CRC), also known as bowel cancer, is an important condition in
Australia, with 13 951 new cases and 4047 deaths from CRC recorded in 2007.1 It was
estimated that over 14 700 Australians would be diagnosed with CRC in 2010, and about
3700 would die from it.2 Australia has one of the highest CRC mortality rates in the world,3
and CRC is Australia’s 10th most important condition in terms of disability-adjusted life-
years lost for men and for women.4 Caring for patients with CRC is also expensive:
Australia spent $235 million in 2001 for direct medical costs of CRC;5 by 2010, expenditure
was estimated to exceed $750 million (Sumitra Ananda, Medical Oncologist, Royal
Melbourne Hospital and BioGrid Australia, personal communication).
Screening has been shown in randomised trials to reduce the incidence of and mortality from
CRC.6,7 Based on this evidence, many developed countries are implementing CRC
screening programs.8 The Australian Government has initiated only a limited CRC
screening program, with a one-time immunochemical faecal occult blood test (iFOBT) for
people aged 50, 55 and 65 years. This is despite National Health and Medical Research
Council (NHMRC) guidelines recommending a full program of biennial faecal occult blood
test (FOBT) screening for those aged over 50 years.9 One of the main barriers to full
implementation has been inadequate funding.10
Modelling offers a means of understanding the costs and potential benefits of CRC
screening, and can be used to help inform decisions about program implementation. A
systematic review of older models of CRC screening performed mainly in United States
settings found CRC screening to be both effective and relatively good value in terms of cost
per life-year gained (LYG).11 However, these models did not consistently include the costs
of program administration and infrastructure or costs of achieving the assumed levels of
participation and adherence. Also, older models and modelling done in other settings, such
as the US or Europe, may not accurately reflect current costs in Australia.
We reviewed relevant existing modelling studies from Australia and performed additional
basic modelling to provide estimates of costs and outcomes from full implementation of
biennial iFOBT screening for adults aged 50–74 years.
METHODS
Literature review
We conducted keyword searches in PubMed, the United Kingdom National Health Service
Economic Evaluation Database (NHS EED; http://www.crd.york.ac.uk/crdweb/) and the US
Tufts Medical Center Cost Effectiveness Analysis Registry
(http:// www.tufts-nemc.org/cearegistry) to identify existing modelling studies and
economic analyses published since 1993. We also reviewed reference lists from published
articles and sought advice from experts to locate other analyses not identified in the database
searches. We focused mainly on modelling studies specific to the Australian setting, but
sought other analyses for parameters or questions that have not been well studied in
Australia. We considered studies that examined costs and cost-effectiveness of FOBT
screening programs compared with no screening program; we did not consider analyses that
only compared two or more screening methods. We standardised costs to 2010 Australian
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dollars using purchasing power parities12 and the Australian Institute of Health and Welfare
Health Price Index.13
Additional modelling
We then performed additional modelling of biennial iFOBT screening for those aged 50–74
years using estimates derived from our literature review, data from the current Australian
screening program, and interviews with screening program staff and Australian content
experts. Our modelling assumptions are outlined in Box 1. We estimated that about five
million Australians would be eligible for screening within the 50–74-years age range,
leading to 2.5 million being offered iFOBT screening each year in a biennial program. We
assumed that the participation rate would be 40% (based on participation in the current
screening program), leading to about one million completed tests per year.15 We also
assumed a 75% follow-up rate after positive FOBTs, and estimated the funds required to
achieve this level of adherence.
We estimated the screening program would reduce bowel cancer mortality by 15%–25%,
based on intention-to-treat analyses of biennial guaiac-based FOBT (gFOBT) randomised
trials (15%)6 and predicted mortality reductions with iFOBT in previous modelling studies,
adjusted for expected participation (25%).11 Risk reductions were applied against an
estimated 2000 deaths per year attributable to CRCs that would otherwise have been
detected by screening in the 50–74-years age group.19 We also assumed that each CRC
death prevented would be associated with an average of 12 LYGs (literature estimates range
from 10 to 14 LYGs17,18).
We assumed an FOBT positivity rate of about 5%, a value slightly lower than that observed
in the current program, to account for effects of increased rescreening in a full screening
program. Of those with positive iFOBTs, we assumed that 3%–5% would have cancer; 20%
advanced adenomas; and 20%– 25% non-advanced adenomas.12,17 Screening program
participants supposed to have adenomas would enter a surveillance program based on
NHMRC guidelines (colonoscopy every 3 years for advanced adenomas; colonoscopy every
5 years for non-advanced adenomas); those with cancer would receive appropriate treatment
and surveillance.9
In the base case, we assumed no treatment cost offsets from screening compared with usual
care. We then examined likely cost offsets resulting from decreased CRC incidence and a
shift to CRC detection at an earlier cancer stage as a result of screening, using newer
estimates of the cost of CRC care.20
Costs were based on estimates from other modelling studies, current program costs, and our
own estimates of the program activities, such as ensuring adherence. We included estimates
of program administrative costs, including general administration, promotion of
participation in screening, adherence support for those undergoing colonoscopy, and the
costs of programs to reduce health disparities or inequity. We assumed information
technology improvements and quality assurance efforts were included in general
administrative costs. We assumed each colonoscopy cost $1300, including the cost of
polypectomy and pathology tests for the 40%–50% of cases in which polyps are detected.
Cancer treatment costs would be accounted for through the usual care system, as is the case
currently.
Because we were concerned with developing better estimates of immediate program costs
and health impact, we did not discount either the benefits or costs of the screening program.
In addition, we did not account for patient-related factors such as patient time costs,21
differences in quality of life, or productivity losses. Previous estimates suggest that the costs
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associated with lost productivity attributable to CRC may be large;5 however, both including
productivity losses in economic evaluation, and the methods used to estimate them, remain
controversial.
1 Modelling assumptions, required resources, costs and cost-effectiveness
Assumptions about participation and adherence
• 5 million average-risk Australians aged 50–74 years*
• 2.5 million would be offered screening each year (biennial screening)
• 1 million would accept based on a 40% participation rate†
• 5% positive findings in the established program, ‡ leading to 50 000 positive
tests per year
• 75% adherence to colonoscopy (with adherence support as below), leading to 37
500 initial diagnostic colonoscopies per year
• 20%–25% of colonoscopies will find large adenomas or cancer§
• 20%–25% of colonoscopies will find smaller, non-high-risk adenomas
• 15 000–20 000 Australians will enter the surveillance colonoscopy program¶
• 75 000 colonoscopies each year total for program, based on 37 500 new
diagnostic and 37 500 surveillance examinations per year
Assumptions about mortality reduction
• 15%–25% reduction in colorectal cancer mortality across the population**
• 12 life-years saved per death prevented††
Cost assumptions
• General program administrative costs, $5.0 million
• 2.5 million initial mailings per year at $4 each, $10.0 million
• 1.5 million reminder letters at $0.67 each, $1.0 million
• 1 million test processing fees at $25 per test, $25.0 million
• 40 000 primary care visits at $35 each,‡‡ $1.5 million
• Improving participation and adherence,§§ $10.0 million
• 75 000 colonoscopies at $1300 per test, inclusive,¶¶ $97.5 million
* Based on demographic statistics as in Bishop et al 2008.14 † Based on faecal occult
blood test screening program to date.15 ‡ Assumption based on expected decrease in
positive findings with ongoing screening. § Based on faecal occult blood test screening
program to date.15,16 ¶ Estimate based on National Health and Medical Research Council
recommendations with incomplete adherence.9 ** Based on estimates from other models
and trials, adjusted to participation.6,11 †† Average of estimates from Burnet et al 200517
and the United States National Cancer Institute.18 ‡‡ Assumption that 80% of patients
with a positive test (likely to be fewer) will see a general practitioner, with $35 being the
estimated cost of reimbursement for GP visit.15 §§ Estimate based on expenditures in the
current faecal occult blood test screening program. ¶¶ Estimated price similar to weighted
average of prices used in Bishop et al 2008.14
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We identified six analyses performed specifically to evaluate the costs and cost-
effectiveness of screening for bowel cancer in Australia (Box 2).14,22–26 Each found that
screening was effective in reducing CRC mortality, with costs per LYG compared with no
screening usually less than $50 000. Three models estimated total annual program costs,
ranging from $39 million ($56 million in 2010 dollars) for biennial gFOBT screening of
people aged 55–69 years to $140 million ($178.5 million in 2010 dollars) for biennial
gFOBT screening of people aged 50–85 years.23,25,14 Existing models all assumed relatively
low treatment costs for advanced CRC, and most did not include costs of ensuring
colonoscopy adherence.
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gFOBT =guaiac-based faecal occult blood test. iFOBT =immunochemical faecal occult blood test. M =million.
nr = not reported.
*
Original analysis cost, with cost standardised to 2010 Australian dollars in parentheses.
†
Stages A, B, C and D according to the Dukes classification.
‡
Using data from Bolin et al 1999.26
§
In 1996 US$ from Bolin et al 1999.26
Additional modelling
Our model estimates that among one million annual participants, 50 000 would have
positive iFOBTs each year, with 37 500 going on to have colonoscopies. In addition, about
37 500 surveillance colonoscopies will be required annually, giving a total of 75 000
colonoscopies per year.
The estimated gross costs of a biennial iFOBT-based program for those aged 50–74 years
were about $150 million per year. The largest single component ($97.5 million) is the cost
of diagnostic and surveillance colonoscopies. The costs of mailing invitations, reminder
letters, processing iFOBTs, and returning iFOBT results would be about $36 million per
year. About $15 million would be budgeted for program administrative costs, including
general administration ($6 million), promoting program participation ($3 million), reducing
inequity ($3 million) and ensuring adherence after positive FOBT results ($3 million).
Our modelled screening program would be expected to reduce mortality from bowel cancer
by 15%–25%, resulting in 300–500 fewer deaths from CRC per year, or 3600–6000 life-
years saved. The undiscounted cost per LYG of screening is estimated to be $25 000–$41
667, consistent with other models we reviewed.
Net costs and additional investment
Our estimates of total program cost and those in the other analyses we reviewed are likely to
be conservative for several reasons. First, they do not account for the ability of screening to
prevent bowel cancer. The Minnesota trial of gFOBT screening found a 17% reduction in
CRC incidence with extended follow-up.27 Based on the use of iFOBT and on our
assumptions about participation, it may be reasonable to expect a 10% reduction in
incidence in the Australian population aged 50–74 years, or 900 fewer cases per year. If we
assume $50 000 in treatment cost savings per case prevented based on newer costs of cancer
care,20 annual savings could be as high as $45 million. Even conservatively assuming a 5%
reduction in incidence would save $27 million.
Second, cost offsets from the more favourable distribution of cancer stage with screening
have not been incorporated in previous models. Accurately accounting for this effect will be
particularly important in the context of rapidly rising costs of treating patients with advanced
bowel cancer.20,28 Screening reduces the proportion of people with metastatic disease at
diagnosis from 18% to 3%, and increases the proportion of those with local disease (Dukes
Stage A) from 17% to over 40%.29 A 10% conversion of cancers from advanced disease to
local disease could be expected to save $27 million (900 cases at $30 000 per case) each
year. Estimates from the Dutch modelling group, using US cost data, suggest that FOBT
screening would become cost-saving (savings from treatment costs would exceed
investment in screening) within 25–30 years, given changing treatment patterns and costs.20
In addition, the actual incremental government expenditures required for full
implementation are also likely to be lower, because many adults in the screening age range
have already had colonoscopies for diagnostic evaluation of symptoms. Currently, over 500
000 colonoscopies are performed each year in Australia, mostly in adults aged 50–74
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years.30 If these procedures are accounted for when assessing screening status, and therefore
program eligibility, the need for additional FOBT and colonoscopies will be lower, with
consequently lower incremental spending. If 20% of the estimated 75 000 annual
colonoscopies are already occurring outside the screening program, then the actual
additional cost of fully implementing the program may be almost $20 million less per year
(15 000 fewer procedures at $1300 each). If efforts are made to promote adherence to
NHMRC guidelines for surveillance, colonoscopy costs may be further reduced, and
available capacity increased, through reducing unnecessary use of surveillance
examinations. 31,32
Accounting for these factors and including the current federal government investment in
CRC screening ($29 million per year), it is likely that the additional investment required to
fully implement screening would be less than $50 million per year (Box 3).
3 Cost offsets and effect on investment required
Cost offsets
• Reduction in colorectal cancer incidence with screening and surveillance, 5%–
10%27
➢ potential annual savings: $27–$45 million
• Effect of stage-shifting on cost (net 10% cancers from Stage D to Stage A*)29
➢ potential annual savings: $27 million
• Cost of colonoscopy complications (1 per 1000 colonoscopies with cost of $15
000 per incident)
➢ potential annual additional costs: $1.1 million
• Net effect: reduction in cost of $53–$71 million annually
Costs currently paid in other health sectors
• Reduction in colonoscopy resources needed as a result of existing ad-hoc
screening
➢ if 20%, would reduce funds required by about $20 million annually
• Current annual spending on screening program: $29 million
• Total screening costs currently paid in other sectors: $49 million
Estimate of additional investment required
• Total estimated gross cost: $150 million
• Savings from cost offsets: $53–$71 million
• Current spending: $49 million
• Total additional investment required: $30–$48 million
* Staging according to the Dukes classification.
DISCUSSION
Our review of existing models of CRC screening in Australia suggests that a program of
biennial iFOBT screening in adults aged 50–74 years is likely to be effective, preventing
300–500 deaths annually, and cost-effective, with costs per LYG generally less than $50
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000. To date, government budgeting constraints and concern about capacity, particularly the
availability of colonoscopy, have led to the adoption of a limited program of one-time
screening for adults aged 50, 55 and 65 years.10 At present, funding for even this limited
program is due to expire in mid 2011 unless it is reauthorised.
Given the increasing costs of treating advanced CRC, our updated modelling suggests that
the implementation of full biennial screening is affordable, with gross annual costs of $150
million offset by $50 million or more in savings from reduced cancer incidence and shifting
of diagnosed cancers to more favourable stages that are less expensive to treat. After
accounting for the current rate of colonoscopies performed outside the screening program
and the current federal government screening program investment, the actual additional
expenditure required is likely to be less than $50 million per annum.
Our estimates of total gross program costs are similar to those from previous models, 14,25
and these costs would be similar to or less than current investment in screening programs for
breast cancer ($120 million in the 2006–07 financial year)33 and cervical cancer ($140
million in 2001).34 One US analysis has found that investment in CRC screening is among
the most valuable of all preventive services.35
In addition to the political and institutional constraints on the development of an evidence-
based bowel cancer screening program, 10 budgetary constraints and concerns about the
adequacy of Australia’s capacity for diagnostic colonoscopy and cancer treatment are factors
that have acted as barriers to the expansion of the program. Our analysis suggests that total
government spending would increase only modestly if the program were expanded to
biennial screening of Australian residents aged 50–74 years. The largest cost component is
that of colonoscopy, determined by both the unit cost of the procedure and the total number
of procedures performed. Efforts to control the unit cost of colonoscopy while maintaining
quality, 31 and to reduce the overuse of colonoscopy for surveillance,32 are important for
ensuring program value.
Concerns about the capacity to perform colonoscopy relate mainly to public-sector capacity,
and could be mitigated through a preferred provider voucher program that would allow
screening program participants to have colonoscopies in public or private settings for a
negotiated fixed cost and with the assurance of quality and safety.18 The recent high growth
rates in colonoscopy procedures suggest that private-sector colonoscopy facilities are able to
meet the additional demand for services.30 Reductions in the overuse of colonoscopy for
surveillance or for ad-hoc screening will also help in this regard.
A limitation of our analysis has been a paucity of data for several key parameters,
particularly the number of colonoscopies required in a full program of screening and
surveillance. There are also insufficient data to estimate the effectiveness or cost-
effectiveness of the current one-time screening program at ages 50, 55 and 65 years; or that
of alternative options to iFOBT, including gFOBT, flexible sigmoidoscopy, or colonoscopy.
We focused on iFOBT because the government has selected it for the national screening
program, and because recent data suggest it may perform better than some other options.36
Our modelling did not examine the full consequences of screening in terms of discounted
quality-adjusted life-years, but its findings are consistent with other, more sophisticated
models, giving us increased confidence in its results. The application of more sophisticated
models may be warranted as additional evidence emerges.
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Consistent evidence suggests that screening for bowel cancer with biennial iFOBT in
Australians aged 50–74 years is both effective (preventing an estimated 300–500 deaths
from bowel cancer each year) and cost-effective. The rising costs of treating advanced
bowel cancer make screening even more compelling. Based on savings from reduced
treatment costs, we estimate that implementation of a full program could be achieved with a
modest additional investment that would bring spending on the program up to a level similar
to that for other cancer screening programs. At present, the bowel cancer screening program
has not been funded beyond mid 2011. It is our hope that our analysis will provide relevant
information for government decisionmakers to weigh the potential benefits and costs of a
full program versus other spending priorities.
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